4 most recent filings and news items mentioning AIDX. Updated every 60 seconds.
OtherAug 5, 2026Neutral
The company released an investor presentation outlining its strategic initiatives and risks for upcoming regulatory approvals and financial projections. Market relevance: Focus on regulatory progress and market strategy.
View filing at SEC.gov →
GuidanceJul 1, 2026Neutral
The company released a July 2026 presentation detailing financial models and clinical data for the OneTest platform. Market relevance hinges on potential FDA authorization and CMS reimbursement rates.
View filing at SEC.gov →
BiotechJun 5, 2026Neutral
U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts
View filing at SEC.gov →
EarningsMay 20, 2026Positive
20/20 BioLabs reported Q1 2026 revenue of $0.4 million and raised $5.0 million in private placement, with cash position of $4.2 million as of March 31, 2026. The company expects meaningful revenue growth in Q2 2026 from Maryland's state-funded firefighter cancer screening program
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.